Elena Parovichnikova, MD,PhD
Nathional Medical Research Center for Hematology Moscow Russia 125167
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elena Parovichnikova, MD,PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:34 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06237192 · MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult PatientsNational Research Center for Hematology, Russia · recruiting · Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Ph3NCT06188676 · Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell LymphomaNational Research Center for Hematology, Russia · active not recruiting · Primary Mediastinal Lymphoma · study director
- Ph2NCT05660993 · Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaNational Research Center for Hematology, Russia · unknown · Hodgkin Lymphoma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.